Briefs: Panacea Biotec, Lotus Eye Hospital and Uflex

Panacea Biotec receives Rs. 315 crore LoA from UNICEF

FDA issues CRL for Sentynl’s copper histidinate for treatment of Menkes disease

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine

Moderna’s mNEXSPIKE generates strong immune response against LP.8.1 variant in humans

Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world

Moderna opens manufacturing and R&D facility in UK

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population

Metropolis Healthcare acquires Ambika Pathology Laboratory

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions